Manufacturer of Controlled Substances; Notice of Registration, 43454-43455 [05-14831]

Download as PDF 43454 Federal Register / Vol. 70, No. 143 / Wednesday, July 27, 2005 / Notices in the amount of $28.25 (25 cents per page reproduction cost) payable to the U.S. Treasury. and enclose a check in the amount of $7.50 (25 cents per page reproduction costs), payable to the U.S. Treasury. Catherine McCabe, Deputy Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 05–14891 Filed 7–26–05; 8:45 am] Robert E. Maher, Jr., Ass’t Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 05–14890 Filed 7–26–05; 8:45 am] BILLING CODE 4410–15–M BILLING CODE 4410–15–M DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Notice of Lodging of Consent Decree Pursuant to the Comprehensive Environmental Response, Compensation, and Liability Act Drug Enforcement Administration In accordance with Departmental policy, 28 CFR 50.7, notice is hereby given that a proposed consent decree in United States v. Murray Pacific Corp., Civil Action No. CO5–5473FDB, was lodged on July 19, 2005, with the United States District Court for the Western District of Washington. The consent decree requires defendants Murray Pacific Corp., Boardman Brown and Mary Jane Anderson, to compensate natural resource trustees for natural resource damages in Commencement Bay, Washington, resulting from releases of hazardous substances. The trustees are the State of Washington, the Puyallup Tribe of Indians, the Muckleshoot Indian Tribe, the National Oceanic and Atmospheric Administration of the United States Department of Commerce, and the United States Department of the Interior. Under the consent decree, defendants will pay $302,00 for natural resource damages and assessment costs. The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed consent decree. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, Department of Justice, Washington, DC 20530, and should refer to United States v. Murray Pacific Corp., DOJ Ref. #90–11–2–1049. The proposed consent decree may be examined at the office of the United States Attorney, 601 Union Street, Seattle, WA 98101. During the public comment period, the Consent Decree may be examined on the following Department of Justice Web site: http:// www.usdoj.gov/enrd/open.html, and at the Consent Decree Library, PO Box 7611, U.S. Department of Justice, Washington, DC 20044–7611 or by faxing a request to Tonia Fleetwood, fax no. (202) 514–0097, phone confirmation number (202) 514–1547. In requesting a copy please refer to the referenced case By Notice dated February 23, 2005, and published in the Federal Register on March 4, 2005, (70 FR 10683), Sigma Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, Massachusetts 01760, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: VerDate jul<14>2003 19:40 Jul 26, 2005 Jkt 205001 Manufacturer of Controlled Substances; Notice of Registration Drug Schedule Cathinone (1235) .......................... Methcathinone (1237) .................. Aminorex (1585) ........................... Alpha-ethyltryptamine (7249) ....... Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ..... 4-Bromo-2,5-dimethoxy-amphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). N-Hydroxy-3,4-methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4-Methylenedioxymethamphetamine (MDMA) (7405). 1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470). Heroin (9200) ............................... Normorphine (9313) ..................... Amphetamine (1100) .................... Methamphetamine (1105) ............ 1-Phenylcyclohexylamine (7460) Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Diprenorphine (9058) ................... Ecgonine (9180) ........................... Levomethorphan (9210) ............... Levorphanol (9220) ...................... Meperidine (9230) ........................ Metazocine (9240) ........................ Methadone (9250) ........................ Morphine (9300) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 I I I I I I I Drug Carfentanil (9743) ......................... Fentanyl (9801) ............................ Schedule II II The company plans to manufacture the listed controlled substances in bulk for laboratory reference standards. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Sigma Aldrich Research Biochemicals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Sigma Aldrich Research Biochemicals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: July 19, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–14834 Filed 7–26–05; 8:45 am] I BILLING CODE 4410–09–P I DEPARTMENT OF JUSTICE I Drug Enforcement Administration I Manufacturer of Controlled Substances; Notice of Registration I I I I I II II II II II II II II II II II II II II II II By Notice dated February 17, 2005, and published in the Federal Register on February 28, 2005, (70 FR 9677), Boehringer Ingelheim Chemical Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Tetrahydrocannabinols (7370), a basic class of controlled substance listed in Schedule I. The company plans to manufacture the listed controlled substance in bulk for use in analysis and drug test standards. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Boehringer Ingelheim Chemical Inc. to E:\FR\FM\27JYN1.SGM 27JYN1 43455 Federal Register / Vol. 70, No. 143 / Wednesday, July 27, 2005 / Notices manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Boehringer Ingelheim Chemical Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: July 19, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–14831 Filed 7–26–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated April 11, 2005 and published in the Federal Register on April 20, 2005 (70 FR 20600), Clinical Trial Services (US), Inc., 2661 Audubon Road, Audubon, Pennsylvania 19403, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Fentanyl (9801), a basic class of controlled substance listed in Schedule II. The company plans to import small quantities of the listed controlled substance in dosage form to conduct clinical trials. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Clinical Trial Services (US), Inc. to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Clinical Trial Services (US), Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the VerDate jul<14>2003 19:40 Jul 26, 2005 Jkt 205001 company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: July 19, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–14825 Filed 7–26–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated February 23, 2005, and published in the Federal Register on March 4, 2005, (70 FR 10679), JFC Technologies, LLC, 100 West Main Street, Bound Brook, New Jersey 08805, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic class of controlled substances listed in Schedule II: Drug Schedule Diphenoxylate (9170) ................... Hydrocodone (9193) ..................... II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of JFC Technologies, LLC to manufacture the listed basic class of controlled substances is consistent with the public interest at this time. DEA has investigated JFC Technologies, LLC to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substances listed. PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 Dated: July 19, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–14836 Filed 7–26–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By notice dated February 23, 2005, and published in the Federal Register on March 4, 2005 (70 FR 10680), Lin Zhi International Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085 made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic class of controlled substances listed in Schedule II: Drug Oxycodone (9143) ........................ Hydrocodone (9193) ..................... Schedule II II The company plans to manufacture the listed controlled substances in bulk for use in analysis and drug test standards. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Lin Zhi International Inc. to manufacture the listed basic class of controlled substances is consistent with the public interest at this time. DEA has investigated Lin Zhi International Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substances listed. Dated: July 19, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–14828 Filed 7–26–05; 8:45 am] BILLING CODE 4410–09–P E:\FR\FM\27JYN1.SGM 27JYN1

Agencies

[Federal Register Volume 70, Number 143 (Wednesday, July 27, 2005)]
[NOTIC]
[Pages 43454-43455]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14831]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated February 17, 2005, and published in the Federal 
Register on February 28, 2005, (70 FR 9677), Boehringer Ingelheim 
Chemical Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made 
application by letter to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of Tetrahydrocannabinols (7370), a 
basic class of controlled substance listed in Schedule I.
    The company plans to manufacture the listed controlled substance in 
bulk for use in analysis and drug test standards.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Boehringer Ingelheim Chemical Inc. to

[[Page 43455]]

manufacture the listed basic class of controlled substance is 
consistent with the public interest at this time. DEA has investigated 
Boehringer Ingelheim Chemical Inc. to ensure that the company's 
registration is consistent with the public interest. The investigation 
has included inspection and testing of the company's physical security 
systems, verification of the company's compliance with state and local 
laws, and a review of the company's background and history. Therefore, 
pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the 
above named company is granted registration as a bulk manufacturer of 
the basic classes of controlled substances listed.

    Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-14831 Filed 7-26-05; 8:45 am]
BILLING CODE 4410-09-P